FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2173769300> ?p ?o ?g. }

• W2173769300 endingPage "1695" @default.
• W2173769300 startingPage "1695" @default.
• W2173769300 abstract "Adherence to oral anticoagulant therapy in secondary stroke prevention – impact of the novel oral anticoagulants Sebastian Luger,1 Carina Hohmann,2 Daniela Niemann,1 Peter Kraft,3 Ignaz Gunreben,3 Tobias Neumann-Haefelin,2 Christoph Kleinschnitz,3 Helmuth Steinmetz,1 Christian Foerch,1 Waltraud Pfeilschifter1 1Department of Neurology, University Hospital Frankfurt, Frankfurt am Main, 2Department of Neurology, Klinikum Fulda gAG, Fulda, 3Department of Neurology, University Hospital Würzburg, Würzburg, Germany Background: Oral anticoagulant therapy (OAT) potently prevents strokes in patients with atrial fibrillation. Vitamin K antagonists (VKA) have been the standard of care for long-term OAT for decades, but non-VKA oral anticoagulants (NOAC) have recently been approved for this indication, and raised many questions, among them their influence on medication adherence. We assessed adherence to VKA and NOAC in secondary stroke prevention. Methods: All patients treated from October 2011 to September 2012 for ischemic stroke or transient ischemic attack with a subsequent indication for OAT, at three academic hospitals were entered into a prospective registry, and baseline data and antithrombotic treatment at discharge were recorded. At the 1-year follow-up, we assessed the adherence to different OAT strategies and patients’ adherence to their respective OAT. We noted OAT changes, reasons to change treatment, and factors that influence persistence to the prescribed OAT. Results: In patients discharged on OAT, we achieved a fatality corrected response rate of 73.3% (n=209). A total of 92% of these patients received OAT at the 1-year follow-up. We observed good adherence to both VKA and NOAC (VKA, 80.9%; NOAC, 74.8%; P=0.243) with a statistically nonsignificant tendency toward a weaker adherence to dabigatran. Disability at 1-year follow-up was an independent predictor of lower adherence to any OAT after multivariate analysis, whereas the choice of OAT did not have a relevant influence. Conclusion: One-year adherence to OAT after stroke is strong (>90%) and patients who switch therapy most commonly switch toward another OAT. The 1-year adherence rates to VKA and NOAC in secondary stroke prevention do not differ significantly between both therapeutic strategies. Keywords: stroke, prevention, vitamin K antagonists, non-VKA oral anticoagulants, adherence" @default.
• W2173769300 created "2016-06-24" @default.
• W2173769300 creator A5003159414 @default.
• W2173769300 creator A5004546807 @default.
• W2173769300 creator A5004747788 @default.
• W2173769300 creator A5022740866 @default.
• W2173769300 creator A5026914010 @default.
• W2173769300 creator A5032828343 @default.
• W2173769300 creator A5041229576 @default.
• W2173769300 creator A5056487867 @default.
• W2173769300 creator A5074466778 @default.
• W2173769300 creator A5089223522 @default.
• W2173769300 date "2015-11-01" @default.
• W2173769300 modified "2023-09-26" @default.
• W2173769300 title "Adherence to oral anticoagulant therapy in secondary stroke prevention &ndash; impact of the novel oral anticoagulants" @default.
• W2173769300 cites W1480729244 @default.
• W2173769300 cites W1558629758 @default.
• W2173769300 cites W1786557664 @default.
• W2173769300 cites W1966242613 @default.
• W2173769300 cites W1968218885 @default.
• W2173769300 cites W1984207232 @default.
• W2173769300 cites W2046112373 @default.
• W2173769300 cites W2051904394 @default.
• W2173769300 cites W2096246254 @default.
• W2173769300 cites W2097854437 @default.
• W2173769300 cites W2106143461 @default.
• W2173769300 cites W2113031260 @default.
• W2173769300 cites W2124247204 @default.
• W2173769300 cites W2132626412 @default.
• W2173769300 cites W2133746099 @default.
• W2173769300 cites W2136489990 @default.
• W2173769300 cites W2154663469 @default.
• W2173769300 cites W2162508946 @default.
• W2173769300 cites W2163777697 @default.
• W2173769300 cites W4246744191 @default.
• W2173769300 cites W4299423054 @default.
• W2173769300 cites W92460100 @default.
• W2173769300 doi "https://doi.org/10.2147/ppa.s88994" @default.
• W2173769300 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4664488" @default.
• W2173769300 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26648702" @default.
• W2173769300 hasPublicationYear "2015" @default.
• W2173769300 type Work @default.
• W2173769300 sameAs 2173769300 @default.
• W2173769300 citedByCount "16" @default.
• W2173769300 countsByYear W21737693002016 @default.
• W2173769300 countsByYear W21737693002017 @default.
• W2173769300 countsByYear W21737693002019 @default.
• W2173769300 countsByYear W21737693002020 @default.
• W2173769300 countsByYear W21737693002021 @default.
• W2173769300 countsByYear W21737693002022 @default.
• W2173769300 countsByYear W21737693002023 @default.
• W2173769300 crossrefType "journal-article" @default.
• W2173769300 hasAuthorship W2173769300A5003159414 @default.
• W2173769300 hasAuthorship W2173769300A5004546807 @default.
• W2173769300 hasAuthorship W2173769300A5004747788 @default.
• W2173769300 hasAuthorship W2173769300A5022740866 @default.
• W2173769300 hasAuthorship W2173769300A5026914010 @default.
• W2173769300 hasAuthorship W2173769300A5032828343 @default.
• W2173769300 hasAuthorship W2173769300A5041229576 @default.
• W2173769300 hasAuthorship W2173769300A5056487867 @default.
• W2173769300 hasAuthorship W2173769300A5074466778 @default.
• W2173769300 hasAuthorship W2173769300A5089223522 @default.
• W2173769300 hasBestOaLocation W21737693001 @default.
• W2173769300 hasConcept C118552586 @default.
• W2173769300 hasConcept C126322002 @default.
• W2173769300 hasConcept C127413603 @default.
• W2173769300 hasConcept C16568411 @default.
• W2173769300 hasConcept C2776301958 @default.
• W2173769300 hasConcept C2777015399 @default.
• W2173769300 hasConcept C2778205648 @default.
• W2173769300 hasConcept C2778661090 @default.
• W2173769300 hasConcept C2779161974 @default.
• W2173769300 hasConcept C2780638905 @default.
• W2173769300 hasConcept C2780645631 @default.
• W2173769300 hasConcept C2781344064 @default.
• W2173769300 hasConcept C2992750412 @default.
• W2173769300 hasConcept C2993590494 @default.
• W2173769300 hasConcept C71924100 @default.
• W2173769300 hasConcept C78519656 @default.
• W2173769300 hasConceptScore W2173769300C118552586 @default.
• W2173769300 hasConceptScore W2173769300C126322002 @default.
• W2173769300 hasConceptScore W2173769300C127413603 @default.
• W2173769300 hasConceptScore W2173769300C16568411 @default.
• W2173769300 hasConceptScore W2173769300C2776301958 @default.
• W2173769300 hasConceptScore W2173769300C2777015399 @default.
• W2173769300 hasConceptScore W2173769300C2778205648 @default.
• W2173769300 hasConceptScore W2173769300C2778661090 @default.
• W2173769300 hasConceptScore W2173769300C2779161974 @default.
• W2173769300 hasConceptScore W2173769300C2780638905 @default.
• W2173769300 hasConceptScore W2173769300C2780645631 @default.
• W2173769300 hasConceptScore W2173769300C2781344064 @default.
• W2173769300 hasConceptScore W2173769300C2992750412 @default.
• W2173769300 hasConceptScore W2173769300C2993590494 @default.
• W2173769300 hasConceptScore W2173769300C71924100 @default.
• W2173769300 hasConceptScore W2173769300C78519656 @default.
• W2173769300 hasLocation W21737693001 @default.
• W2173769300 hasLocation W21737693002 @default.
• W2173769300 hasLocation W21737693003 @default.

• next